Novel Buccal Delivery of Cisplatin, Targeting Oral Cancer

Technology #15754

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Schematic of this work's nanotechnology. CHI is the main component for building the particle. It is a biodegradable, mucoadhesive compound that is FDA approved as safe (GRAS).Novel Patch offers NP loaded front end that adheres to the mucus and a non­permeable back end that performs dual function: (1) Prevents drug loss, (2) Provides platinum taste masking
Categories
Inventors
Manijeh Goldberg
Koch Institute for Integrative Cancer Research, MIT
Maria Fernandez
Koch Institute for Integrative Cancer Research, MIT
Kuan-Ju Chen
Koch Institute for Integrative Cancer Research, MIT
Managed By
Jon Gilbert
MIT Technology Licensing Officer
Patent Protection

Targeted Buccal Delivery of Agents

US Patent Pending 2014-0234212
Publications
Development of a Nanoparticle-Embedded Chitosan Sponge for Topical and Local Administration of Chemotherapeutic Agents
J Nanotechnol Eng Med., November, 2014

Applications

This invention is a buccal drug delivery platform which topically targets oral cancer cells in the mouth for improved treatment of oral cancer.

Problem Addressed

While the prevalence of many cancers is decreasing, the incidence of oral cancer (OC) has been increasing with over 640,000 cases diagnosed annually. Despite the fact that OC treatment is incredibly expensive with an annual cost of care of ~$80,000 per patient for medical, pharmacy, and dental care, an amount which doubles when surgery, radiation, and chemotherapy are combined, OC has only a 50% five year survival rate. This technology treats OC by replacing intravenous (IV) delivery with topical and buccal delivery, significantly reducing the overall cost of OC treatment, by more effectively delivering cisplatin (CIS) to oral cancer cells and reducing toxicity in healthy tissue.

Technology

This invention is a safe and effective nanoparticle (NP) drug delivery system for the local treatment of non-metastatic OC, which accounts for 90% of OC. The controlled release NP design will dispense a steady amount of the drug that targets the cancer tissues while minimizing toxic side effects to the surrounding healthy tissues and comprises of the active drug compound CIS, the NP polymer chitosan (CHI), chemical linker poly(ethylene glycol) (PEG), and the targeting moiety arginylglycylaspartic acid (RGD). The NPs will be delivered via a bilayer sponge placed directly on the tumor with NPs in one layer and a plasticized, non-porous, non-permeable layer that forces a unidirectional NP release. PEG and CHI increase drug permeability while RGD peptide provides active targeting. The nano encapsulation of CIS offers a number of benefits including increased protection from CIS on healthy cells, high drug loading, controlled release, improved permeability, increased bioadhesivity, and masking of CIS’s metallic taste. Furthermore, patients may administer CIS in their own homes, avoiding the inconvenience and expense of chemotherapy clinics encouraging early treatment to significantly raise survival rate.

Advantages

  • Less toxic, easy to dose, and convenient, allowing patients to self-administer early treatment at home
  • Safe and effective controlled release for local treatment
  • Targeting to cancer cells minimizes toxic side effects
  • High drug permeability
  • No undesirable metallic taste of platinum